BGLC vs. XGN, RNLX, PMD, CNTG, OPGN, ACON, DMTK, FRES, NVTA, and MDXH
Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Exagen (XGN), Renalytix (RNLX), Psychemedics (PMD), Centogene (CNTG), OpGen (OPGN), Aclarion (ACON), DermTech (DMTK), Fresh2 Group (FRES), Invitae (NVTA), and MDxHealth (MDXH). These companies are all part of the "medical laboratories" industry.
Exagen (NASDAQ:XGN) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment.
Exagen presently has a consensus target price of $7.00, suggesting a potential upside of 248.26%. Given BioNexus Gene Lab's higher possible upside, analysts clearly believe Exagen is more favorable than BioNexus Gene Lab.
Exagen received 20 more outperform votes than BioNexus Gene Lab when rated by MarketBeat users.
In the previous week, Exagen had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 3 mentions for Exagen and 2 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 0.96 beat Exagen's score of 0.25 indicating that Exagen is being referred to more favorably in the media.
75.3% of Exagen shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 26.1% of Exagen shares are owned by company insiders. Comparatively, 6.8% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
BioNexus Gene Lab has a net margin of -27.24% compared to BioNexus Gene Lab's net margin of -34.74%. Exagen's return on equity of -30.74% beat BioNexus Gene Lab's return on equity.
BioNexus Gene Lab has lower revenue, but higher earnings than Exagen.
Summary
Exagen beats BioNexus Gene Lab on 8 of the 13 factors compared between the two stocks.
Get BioNexus Gene Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNexus Gene Lab Competitors List
Related Companies and Tools
